InVivoSIM anti-human amyloid beta (Donanemab Biosimilar)

About InVivoSIM anti-human amyloid beta (Donanemab Biosimilar)

This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Donanemab, making it ideal for research use. Donanemab is a humanized IgG1κ anti-human APP antibody, and it specifically reacts with abeta 42 (Aβ42), a pyroglutamate form of Aβ that is aggregated in amyloid plaques during the pathogenesis of Alzheimer’s disease (AD). Aβ42 results from an aberrant processing of amyloid-β protein precursor (APP or AβPP). The initial cleavage of APP is caused by either α- secretase or β-secretase (or BACE1). sAPPα and the α-C-terminal fragment (α-CTF or APP-C83) are produced by α-secretase cleavage of APP, whereas sAPPβ and the β-C-terminal fragment (β-CTF or APP-C99) are produced by β-secretase cleavage. γ-secretase further cleaves C83 and C99, yielding the P3 peptide and Aβ, respectively. Depending on the location of the γ-secretase cleavage, Aβ can have a length of 37-43 amino acids in its peptide sequence. The two main Aβ species are Aβ42 and Aβ40. In early AD pathology, Aβ species play a critical role by seeding toxic oligomeric species with Aβ42 being more preferentially depositing in amyloid plaques than Aβ40. Donanemab specifically recognizes Aβ p3-42 (Aβ42) and it is reported to impede the progression of AD by clearing plaques through microglial-mediated phagocytosis in mice without causing microhemorrhages. Donanemab biosimilar antibodies are commonly used for in vitro and in vivo studies involving Alzheimer's disease and Down syndrome experimental models.